بررسی بیان ژن Survivin و واریانت پیرایشی جدید Survivin

بررسی بیان ژن Survivin و واریانت پیرایشی جدید Survivin

Survivin-2a
Survivin
*
*
Downloaded from umj.umsu.ac.ir at 8:03 IRST on Wednesday March 8th 2017
1391/09/28 :
1391/07/01 :
:
(CML)
.
Survivin
CML
Survivin
.
Survivin-2a
.
CML
.
Survivin-2a Survivin
.
:
CML
Survivin-2a
.
Survivin
( AP/BC)
(CP)
(RT-PCR )
.
.
Survivin-2a
CP
AP/BC
AP/BC
.
Survivin-2a
:
Survivin
CP
AP/BC
.
CP
.
AP/BC
Survivin
:
Survivin-2a
:
Survivin-2a Survivin
-
:
:
Email: [email protected]
.( )
(
)
CML
Bcr
Abl
Bcr-Abl
.(
.(
)
Bcr-Abl
.( )
CML
)
)
)
-
Chronic myeloid leukemia(CML)
CML
.
Survivin .( )
(IAP)
Downloaded from umj.umsu.ac.ir at 8:03 IRST on Wednesday March 8th 2017
CML
.
Bcr-Abl
.( )
Survivin
.
(
)
CML
.( )
.
Survivin
.( )
.
E4
E3 E2 E1
3B 2B
Survivin
:
Ex3 3
.( )
2
RNA
) EDTA
.( )
PBS
(
)
ml
Survivin
Survivin-2a
.( )
rpm
.( )
Survivin
.( )
PBS
.
RNA
.
Survivin
-
:(RT-PCR )
.( )
RNA
RNA
.
(
Teifarafarayand) Rimazoles
RNA
.
Rimazoles
Merck )
Merck )
RNA
Survivin-2a
.
) EDTA % /
Merck )
RNA
Survivin
.( )
.
UV
)
Survivin-2a
.
RNA
(
(
) DNase
(
CML
) oligo dT
Phosphate Buffer Saline
Survivin-2a
.
1
3
.( - )
Survivin
2
Inhibitor of apoptosis protein
Alternative splicing
...
Survivin-2a
Survivin
) RevertAidTM M-MLV
cDNA
) CML
(
Nested PCR
2m
Downloaded from umj.umsu.ac.ir at 8:03 IRST on Wednesday March 8th 2017
.
.
(AP/BC)
Survivin-2a
(CP)
.(
)
(
) Operon
AP/BC
PCR
PCR
.
Survivin
.
MgCl2
Taq
cDNA
/
/
/ mM dNTP / mM
x
) / unit /
RT-PCR
.
Survivin-2a
.
PCR
µl
/ µM
Survivin-2a
RT-PCR
Survivin-2a
CML
.
PCR
ºC
C
º C Annealing
Survivin-2a
.
Survivin-2a
(
2m
Eurofins MWG
CP
.
Survivin
)
º
º C Final Extension
º C Extension
AP/BC
.
CP
Survivin
ºC
SurvivinCP
2m
.( P= /
AP/BC
º C
2a
)
2m
ºC
Annealing
º C Final Extension
º C Extension
Survivin-2a
CP
.
PCR
.
PCR
P= /
/ (
.
AP/BC
)
(
)
Survivin-2a
% /
Survivin
Survivin-2a
UVItec
.
)
.
Survivin
Survivin
Survivin
( 2m
SPSS 14.0
AP/BC
Survivin
.(
)
one-way ANOVA
P< /
CP
CP
Survivin
CP
2m
1
2 microglobulin
P= /
Survivin
.( P= / )
AP/BC
.
2m
.
Survivin-2a Survivin
:( )
2m
.
Downloaded from umj.umsu.ac.ir at 8:03 IRST on Wednesday March 8th 2017
CP
:(NM004048) 2m
PCR
5'- CTA CTC TCT CTT TCT GGC CTG-3´
5'- GAC AAG TCT GAA TGC TCC AC-3´
.
:(AY795969) Survivin-2a
PCR
5'-TGG CAG CCC TTT CTC AAG-3'
5'- AAC CCT CCC ATA CTA AGT GTC -3'
5'-ACC ACC GCA TCT CTA CAT TC- 3'
5'- AAC CCT CCC ATA CTA AGT GTC -3'
.
PCR
:(NM001168) Survivin
5'-TGG CAG CCC TTT CTC AAG-3'
5'-GAG AGA GAG AAG CAG CCA C-3'
5'-ACC ACC GCA TCT CTA CAT TC- 3'
5'- CTG GTG CCA CTT TCA AGA C -3'
:( )
CML
( - )
CP/ AP/BC
Normal
CP
AP/BC
Marker
Survivin-2a (266 bp)
2m (191 bp)
RT-
Survivin-2a
.CML
.
( )
.
:( )
Survivin-2a
(
) CP AP/BC
PCR
...
Survivin-2a
Survivin
P<0/05
4.5
Survivin-2a/ 2m value
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
AP/BC
CP AP/BC
P< /
CP
Normal
. 2m
Survivin-2a
.
2m .
Survivin-2a
UVItec
:( )
RT-PCR
.
P=0/000007
4.5
P=0/4
4.0
Survivin/ 2m value
Downloaded from umj.umsu.ac.ir at 8:03 IRST on Wednesday March 8th 2017
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
AP/BC
CP AP/BC
P< /
CP
. 2m
Survivin
.
2m .
.
Normal
Survivin
UVItec
:( )
RT-PCR
Survivin
Survivin-2a
.
Survivin
Survivin
.( )
Downloaded from umj.umsu.ac.ir at 8:03 IRST on Wednesday March 8th 2017
Survivin-2a
ALL
.( - )
Daoy
CML
AML
.( )
Survivin-2a
Survivin
- )
.(
.( )
Speletas
CML
Survivin
Survivin-2a
Survivin-2a
.
.( )
.( )
Survivin-2a
.( )
Bcr-Abl
CML
b2a2
.
CML
b3a2
Survivin-2a
b2a2
.( )
Survivin-
.
Survivin-2a
CML
AP/BC
.( )
Survivin
CML
2a
AP/BC
Survivin-2a
.
Speletas
CP
Survivin-2a
Survivin
CML
CML
Survivin-2a
.
.
Survivin
Suvivin-2a
.
AP/BC
CP
Survivin
CML
Survivin-2a
AP/BC
.
Survivin
Survivin-2a
.
.
1
2
Acute lymphoid leukemia
Acute myeloid leukemia
Survivin
...
References:
Downloaded from umj.umsu.ac.ir at 8:03 IRST on Wednesday March 8th 2017
1.
2.
4.
Faderl S, Talpaz M, Estrov Z, O’Brien S,
Emadi Baygi M. Detection of survivin gene
Kurzrock R, and Kantarjian HM. The biology of
expression in formalin-fixed paraffin-embedded
chronic myeloid leukemia. N Engl J Med 1995;
tissues of human osteosarcoma: its potential
341 (3): 164-72.
usfulness in diagnosis and prognosis of bone
Clarkson B, Strife A, Wisniewski D, Lambek CL,
tumors. Iran Biomed J 2006; 10 (1): 39-45.
Liu C. Chronic myelogenous leukemia as a
(Persian)
6.
7.
8.
9.
14. Kyani K, Hosseinpour Feizi MA, Babaei E,
strategies. Leukemia 2003; 17: 1211-62.
Montazeri V, Halimi M. Evaluation of the
Quintas-Cardama A, Cortes JE. Chronic myeloid
expression of Survivin-2
leukemia: diagnosis and treatment. Mayo Clin
molecular marker in thyroid cancer. Sci J
Proc 2006; 81(7): 973-88.
Kurdistan Univ Med Sci 2009; 14 (3): 25-33.
Goldman JM. Initial treatment for patients with
(Persian)
CML. Hematology Am Soc Hematol Educ
5.
Survivin
13. Babaei E, Mowla SJ, Shariat Torbaghan Sh,
paradigm of early cancer and possible curative
3.
Survivin-2a
15. Sarela
AI,
Macadam
splice variant as a
RCA,
Farmery
SM,
Program 2009; 1: 453-60.
Markham AM, Guillou PJ. Expression of the anti
Frazer R, Irvine AE, McMullin M. Chronic
apoptosis gene, survivin, predicts death from
myeloid leukaemia in the 21st century. Ulster
recurrent colorectal carcinoma. Gut 2000; 46 (5):
Med J 2007; 76 (1): 8-17.
645-50.
Hirose M. Biology and modulation of multidrug
16. Vallbohmer D, Drebber U, Schneider PM, Baldus
resistance (MDR) in hematological malignancies.
S, Bollschweiler E, Brabender J, et al. Survivin
Int J Hematol 2002; 76 (2): 206-11.
expression in gastric cancer: Association with
Deveraux QL, Reed JC. IAP family proteins-
histomorphological
suppressors of apoptosis. Genes Dev 1999; 13 (3):
therapy and prognosis. J Surg Oncol 2009; 99 (7):
239-52.
409-13.
response
to
neoadjuvant
a
17. Atlasi Y, Mowla SJ, Ziaee AM. Differential
bifunctional inhibitor of apoptosis protein. Vet
expression of survivin and its splice variants,
Phathol, 2004; 41(6): 566-607.
survivin-DEx3 and survivin-2B, in bladder cancer.
Ryan BM, O’Donovan N, and Duffy MJ.
Cancer Detect Prevent 2009; 32 (4): 308-13.
Survivin: A new target for anti-cancer therapy.
18. Tirro E, Consoli ML, Massimino M, Manzella L,
Johnson
ME,
Howerth
EW.
Survivin:
Cancer Treat Rev 2009; 35 (7): 553-562.
Francesco F, Sciacca L, et al. Altered expression
10. Li F. Role of survivin and its splice variants in
of c-IAP, survivin, and smac contributes to
tumorigenesis. Br J Cancer 2005; 92 (2): 212-216.
chemotherapy resistance in thyroid cancer cells.
11. Caldas H, Honsey LE and Altura RA. Survivin 2a:
a novel Survivin splice variant expressed in
Cancer Res. 2006; 66 (8): 4263-72.
19. Wajapeyee N, Britto R, Ravishankar HM,
human malignancies. Mol cancer 2005; 4 (11): 1-
Somasundaram
9.
activator protein 2alpha involves transcriptional
12. Fukuda S, Pelus LM. Survivin a cancer target with
an emerging role in normal adult tissues. Mol
Cancer Ther 2006; 5 (5): 1087-98.
K.
Apoptosis
induction
by
repression of Bcl-2. J Biol Chem 2006; 281:
16207-19.
20. Conte E, Stagno F, Guglielmo P, Scuto A, Consoli
C, Messina A. Survivin expression in chronic
myeloid leukemia. Cancer Lett 2005; 225(1): 10510.
21. Mori A, Wada H, Nishimura Y, Okamoto T,
Takemoto Y, and Kakishita E. Expression of the
Downloaded from umj.umsu.ac.ir at 8:03 IRST on Wednesday March 8th 2017
antiapoptosis gene survivin in human leukemia.
Int J Hematol 2002; 75 (2): 161-5.
23. Zhengjiang C, Lihua H, Wenrong F, Qin Z and
Xiaofeng L. Expression of survivin and its splice
variants in gastric cancer. J Huazhong Univ Sci
Tech 2007; 27(4): 393-8.
24. Speletas
M,
Argentou
N,
Karanikas
V,
Gramoustianou ES, Mandala E, Braimi M, et al.
22. Sadek H, Ragab S, Rasmy H, Guindy NME, Ezzat
Survivin isoform expression patterns in CML
W, Hamed M. Expression of the antiapoptotic
patients correlate with resistance to imatinib and
gene survivin in acute leukemias. J Am Sci 2010;
progression, but do not trigger cytolytic responses.
6 (10): 1272-82.
Clin Immunol 2011; 139 (2): 155-63.